Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- FDA Accepts Eisai’s Fycompa for Pediatric Indication Review
June 1, 2018
- Astellas Files Japan NDA for JAK Inhibitor Peficitinib in RA
June 1, 2018
- Kissei’s Spinocerebellar Ataxia Treatment Fails to Hit Primary Targets in Japan PIII Study
June 1, 2018
- 3 Japan Drug Makers Launch Industry-Academia Consortium on Drug Discovery for Immune-Mediated Inflammatory Diseases
June 1, 2018
- Takeda Licenses Relugolix to ASKA in Women’s Health Field
June 1, 2018
- Perspective on Takeda/Shire Deal - 3: Takeda Shareholders Got Short End of the Stick
May 31, 2018
- Japan’s 1st Enbrel Biosimilar Makes Its Debut
May 31, 2018
- FDA Action Date for Mogamulizumab Extended for 3 Months: Kyowa Kirin
May 31, 2018
- Kowa to Launch Parmodia after Skipping 3 Listing Rounds
May 30, 2018
- Astellas’s Gilteritinib Gets FDA Priority Status
May 30, 2018
- Perspective on Takeda/Shire Deal - 2: Acquisition Might Mint More Investment Opportunities, Positive or Negative Not Yet Clear
May 30, 2018
- Chugai Files Actemra for Cytokine Release Syndrome
May 30, 2018
- Janssen Japan Chief Calls for Appropriate Rewards for Innovative Drugs
May 29, 2018
- Perspective on Takeda/Shire Deal - 1: Profits Delivered by On-Market Products More Important than Pipeline
May 29, 2018
- Pfizer Submits New Drug Application in Japan for Dacomitinib
May 29, 2018
- MSD Launches Prevymis for Prevention of CMV Infection
May 29, 2018
- JCR to Start PII Study of Hunter Syndrome Treatment in Brazil in June
May 29, 2018
- European Regulator Accepts Mitsubishi Tanabe’s Edaravone Filing for ALS
May 29, 2018
- Takeda Sales Reps Heavily Pitch Inisync, Takecab in February: Anterio Ranking
May 28, 2018
- FDA Extends Action Date for Lenvima’s HCC Indication by 3 Months
May 28, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…